In Q4'25, SG&A Expenses for APH reached $691M USD, marking the highest point in the observed period, while R&D Expenses remained at no data across all quarters. This latest data point reflects a continued upward trajectory in operational costs driven solely by SG&A, with no contribution from R&D. From Q1'23 to Q4'25, SG&A Expenses exhibited a consistent upward trend, increasing from $346M USD to $691M USD, representing a roughly 100% growth over the 12-quarter span, with notable acceleration in 2024 and 2025 (e.g., quarterly jumps exceeding $50M USD in later periods). R&D Expenses showed no data throughout, indicating a potential focus on sales, general, and administrative functions without reported research investments; the stacked bar chart highlights SG&A as the dominant component of total operating expenses, underscoring rising cost pressures amid business expansion.